Roundtable: from innovation to commercialisation - Part II: the valley of death
29 June, 2010 by Tim DeanIn this section of the roundtable the panellists discussed the so-called 'valley of death' between a promising discovery and having a product that the industry will actually put money behind.
Amgen ready to go shopping
28 June, 2010 by David BinningGlobal biotech company Amgen has acknowledged that proposed changes to the R&D tax credit arrangements would increase the appeal of the Australian biotech industry as the company prepares to embark on a global spending spree.
Roundtable: from innovation to commercialisation - Part I: research and business
28 June, 2010 by Tim DeanIt's the perennial question: how do we effectively translate cutting edge research into successful products in the market? Australian Life Scientist brought together a panel of industry luminaries to discuss the challenges of commercialisation in Australia.
Market report: Jitters return following poor U.S economic data
25 June, 2010 by David BinningAustralian shares slumped to a fortnightly low on Friday, weighed down by concerns about the U.S and Europe as well as uncertainty surrounding the proposed resources super profits tax (RSPT).
ImpediMed clears final U.S hurdle for biompedance product
25 June, 2010 by David BinningBrisbane biotech ImpediMed announced today that it has received a Category III coding from the American Medical Association ( AMA ) for the use of its L-Dex U400 bioimpedance spectroscopy ( BIS ) technology in the detection of lymphoedema in limbs, which will take effect on January 1 next year.
First cannabis-based drug approved in Europe
25 June, 2010 by David BinningThe first cannabis-based pharmaceutical product has been approved in the UK, paving the way for widespread adoption throughout Europe.
Market Report: Cautious end to upbeat week
18 June, 2010 by David BinningThe Australian stock market finished the week up one percent, although thin trade volumes today suggested that investors were exercising caution amid ongoing global uncertainty.
Patrys expands anti-cancer pipeline
18 June, 2010 by Tim DeanPatrys has expanded its pipeline of antibody-based treatments for cancer with two new additions, bringing its portfolio to 13 antibodies under development.
Local scientists take toxic sting out of fire-fighting-foam
18 June, 2010 by David BinningAustralian scientists have developed a technology for isolating the toxic chemicals escaping into the environment for the last 50 years from fire-fighting-foams.
SA scientist pioneers new system for organic waste
17 June, 2010 by David BinningA biotechnologist from the South Australian Research and Development Institute ( SARDI ) has demonstrated a unique ‘waste-food-chain’ with major implications for industries that product organic waste.
New study reveals role of gut hormone in insulin and blood sugar levels
17 June, 2010 by Staff WritersAn Australian and a British researcher have published the results of a breakthrough study expected to transform traditional thinking about the digestive process and possibly lead to new treatments for and other diseases.
Healthscope to provide OvPlex ovarian cancer test in Australia
15 June, 2010 by Staff WritersMelbourne biotech HealthLinx announced today that it will resume distribution its OvPlex ovarian cancer biomarker test through Healthscope’s national network of collection centres after the healthcare provider’s acquisition of ARL Pathology last year.
Market report: Local shares rise on U.S optimism about China and Europe
11 June, 2010 by David BinningThe Australian share market rose today following a strong lead from U.S markets overnight after China reported robust export data and European markets reversed some of their recent losses.
Avita’s ReCell spray-on-skin nearing U.S approval
10 June, 2010 by David BinningAvita Medical has announced exceptional results following the first FDA-approved treatment of a U.S burns patient with the company’s ReCell spray-on-skin treatment.
British biotech boasts antibiotic breakthrough
09 June, 2010 by David BinningA British biotech company is preparing for phase II trials of a new antibiotic being viewed as a major leap forward in the fight against drug -resistant strains of bacteria.
